# Idenix Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/idenix-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.idenix.com
- Total disclosed funding: $56M
- Latest round: Series C (May 14, 2001)
- Investors on record: 10

## About

Idenix Pharmaceuticals, Inc. (f.k.a. Novirio Pharmaceuticals Limited) is engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases.

## Funding rounds

- Series C, May 14, 2001, $44M — GCM Grosvenor, Swiss Life Asset Management, TVM Capital Life Science, Novartis Venture Fund, Banc of America Securities, Nomura Asset Management, MPM BioImpact, AV Holding, Biomedical Sciences Investment Fund, Hanseatic Corporation
- Series A, Dec 14, 1998, $12M — MPM BioImpact

## Investors

- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series C
- GCM Grosvenor — Series C
- Swiss Life Asset Management — Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series C
- Banc of America Securities — Series C
- Nomura Asset Management (https://capitalatlas.ai/funds/nomura-asset-management) — Series C
- AV Holding — Series C
- Biomedical Sciences Investment Fund — Series C
- Hanseatic Corporation (https://capitalatlas.ai/funds/hanseatic-corporation) — Series C